Is Corbus Pharmaceuticals Holdings Inc (CRBP) A Good Stock To Buy?
In this article we are going to use hedge fund sentiment as a tool and determine whether Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) is a good investment right now.
Corbus Pharmaceuticals Holdings Inc. (CRBP)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Knoll Capital Management Fred Knoll | 5,045,870 | $2,684 | 1.68% | |
| 2. | Renaissance Technologies Jim Simons | 1,157,191 | $615 | +371% | 0% |
| 3. | Ikarian Capital Neil Shahrestani | 997,627 | $530 | +6% | 0.06% |
| 4. | D E Shaw D. E. Shaw | 982,916 | $522 | +20% | 0% |
| 5. | Millennium Management Israel Englander | 494,050 | $263 | -27% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.30 | 12,000 | Officer | 179,272 | 2022-05-16 | Filing | |
| $0.25 | 10,500 | Officer, Director | 94,430 | 2022-05-16 | Filing | |
| $0.37 | 10,000 | Officer | 22,000 | 2022-03-10 | Filing | |
| $0.37 | 15,000 | Officer | 167,272 | 2022-03-10 | Filing | |
| $0.37 | 8,600 | Officer, Director | 83,930 | 2022-03-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.75 | 87,500 | Officer | 349,610 | 2020-12-21 | Filing | |
| $1.40 | 53,610 | Officer | 349,610 | 2020-12-18 | Filing | |
| $1.32 | 36,923 | Officer | 349,610 | 2020-12-16 | Filing | |
| $3.04 | 200,000 | Large Shareholder | 3,594,846 | 2015-08-19 | Filing | |
| $2.82 | 30,000 | Large Shareholder | 3,794,846 | 2015-07-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 11,323,000 | $5,795 | 0.11% | |
| 2. | 4,766 | $2,533 | 0% | |
| 3. | 4,292,163 | $2,282 | 0% | |
| 4. | 3,754,954 | $1,996 | 0% | |
| 5. | 2,556,573 | $1,358 | 0% |
News See All
Is CRBP A Good Stock To Buy Now?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.
Corbus Pharmaceuticals Holdings Inc (CRBP): Are Hedge Funds Right About This Stock?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Are Selling Corbus Pharmaceuticals Holdings Inc (CRBP)
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and...
Were Hedge Funds Right About Selling Corbus Pharmaceuticals (CRBP)?
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock.
25 Biggest Marijuana Companies in the World
What are the biggest marijuana companies in the world? If you are looking for the safest investment, marijuana companies may just be the next big thing.
Look Beyond Pharma to Invest in Marijuana Industry
In this article we are going to present an alternative to weed stocks such as GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Cara Therapeutics Inc (NASDAQ:CARA), Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE...
Why The Corbus Pharmaceuticals Holdings Inc (CRBP) Cystic Fibrosis Results Are Very Positive
Last week, Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced data from a Phase II study of its lead development asset Anabasum.
What’s Happening In Financial Markets Today?
U.S. stocks rose on Thursday, with the advance gaining momentum throughout the session as financial shares rallied in response to a positive read on economic growth.
Corbus Pharmaceuticals Holdings Inc (CRBP) Share Offering Hints At $7 Floor With Threatening Short Squeeze
In most cases, equity financings below market are bad news for shareholders. There are exceptions though.
Billionaire Hedge Funds
